Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Medtronic
Express Scripts
Baxter
Johnson and Johnson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR FINACEA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Finacea

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01038869 ↗ Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Bayer Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01038869 ↗ Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Derm Research, PLLC Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01139008 ↗ Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01139047 ↗ Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Finacea

Condition Name

Condition Name for Finacea
Intervention Trials
Rosacea 6
Skin Manifestations 2
Rosacea, Papulopustular 1
Acne Rosacea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Finacea
Intervention Trials
Rosacea 8
Skin Manifestations 2
Hyperpigmentation 1
Acne Vulgaris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Finacea

Trials by Country

Trials by Country for Finacea
Location Trials
United States 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Finacea
Location Trials
North Carolina 4
Kentucky 3
Texas 3
Florida 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Finacea

Clinical Trial Phase

Clinical Trial Phase for Finacea
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Finacea
Clinical Trial Phase Trials
Completed 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Finacea

Sponsor Name

Sponsor Name for Finacea
Sponsor Trials
Bayer 3
Derm Research, PLLC 2
Galderma Laboratories, L.P. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Finacea
Sponsor Trials
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Dow
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.